[go: up one dir, main page]

MA28036A1 - Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil - Google Patents

Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil

Info

Publication number
MA28036A1
MA28036A1 MA28869A MA28869A MA28036A1 MA 28036 A1 MA28036 A1 MA 28036A1 MA 28869 A MA28869 A MA 28869A MA 28869 A MA28869 A MA 28869A MA 28036 A1 MA28036 A1 MA 28036A1
Authority
MA
Morocco
Prior art keywords
treatment
oxcarbazepine
sleep
pain
improvement
Prior art date
Application number
MA28869A
Other languages
English (en)
Inventor
Donald Manning
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320637A external-priority patent/GB0320637D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28036A1 publication Critical patent/MA28036A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouvelles utilisations d'un dérivé de carbamazépine de formule (I) et de ses sels pharmaceutiquement acceptables. L'invention concerne en particulier un régime amélioré d'administration dudit dérivé de carbamazépine de formule (I) et desdits sels pharmaceutiquement acceptables dans le traitement de patients souffrant de douleurs, notamment de douleurs liées à la neuropathie, en particulier à la neuropathie diabétique, et dans l'amélioration du sommeil. L'invention concerne également l'utilisation d'oxcarbazépine dans la fabrication d'une composition pharmaceutique destinée à traiter la douleur ou d'une composition pharmaceutique destinée à améliorer le sommeil de patients souffrant de douleurs chroniques. L'invention concerne encore des compositions pharmaceutiques contenant de l'oxcarbazépine comme seul principe actif, destinées à traiter la douleur ou à améliorer le sommeil de patients souffrant de douleurs chroniques. L'invention concerne enfin des emballages contenant une composition pharmaceutique ayant pour seul principe actif de l'oxcarbazépine, ainsi que des instructions relatives au traitement de la douleur ou à l'amélioration du sommeil de patients souffrant de douleurs chroniques.
MA28869A 2003-09-03 2006-03-10 Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil MA28036A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0320637A GB0320637D0 (en) 2003-09-03 2003-09-03 Organic compounds
US53737804P 2004-01-16 2004-01-16

Publications (1)

Publication Number Publication Date
MA28036A1 true MA28036A1 (fr) 2006-07-03

Family

ID=34276821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28869A MA28036A1 (fr) 2003-09-03 2006-03-10 Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil

Country Status (18)

Country Link
US (1) US20060270658A1 (fr)
EP (1) EP1663247B1 (fr)
JP (1) JP2007513056A (fr)
KR (1) KR20060118426A (fr)
AT (1) ATE446759T1 (fr)
AU (1) AU2004268381B2 (fr)
BR (1) BRPI0414112A (fr)
CA (1) CA2537060A1 (fr)
DE (1) DE602004023861D1 (fr)
IL (1) IL173822A0 (fr)
IS (1) IS8373A (fr)
MA (1) MA28036A1 (fr)
MX (1) MXPA06002392A (fr)
NO (1) NO20061515L (fr)
RU (1) RU2369393C2 (fr)
SG (1) SG146631A1 (fr)
TN (1) TNSN06072A1 (fr)
WO (1) WO2005020968A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
US7722898B2 (en) * 2006-04-26 2010-05-25 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR102486435B1 (ko) 2022-04-25 2023-01-10 주식회사 제이비플랜트 산업용 냉동기기의 친환경 패널의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
WO2004035041A1 (fr) * 2002-10-17 2004-04-29 Novartis Ag Composition pharmaceutique pour le traitement de la douleur comprenant de l'oxycarbazepine, ou certains de ses derives, et inhibiteurs de cox2

Also Published As

Publication number Publication date
DE602004023861D1 (de) 2009-12-10
IL173822A0 (en) 2006-07-05
AU2004268381B2 (en) 2009-06-18
NO20061515L (no) 2006-06-06
EP1663247A2 (fr) 2006-06-07
WO2005020968A3 (fr) 2005-05-19
MXPA06002392A (es) 2006-06-20
TNSN06072A1 (en) 2007-10-03
CA2537060A1 (fr) 2005-03-10
US20060270658A1 (en) 2006-11-30
SG146631A1 (en) 2008-10-30
RU2006110550A (ru) 2007-12-20
IS8373A (is) 2006-03-24
BRPI0414112A (pt) 2006-10-31
AU2004268381A1 (en) 2005-03-10
RU2369393C2 (ru) 2009-10-10
EP1663247B1 (fr) 2009-10-28
WO2005020968A2 (fr) 2005-03-10
JP2007513056A (ja) 2007-05-24
KR20060118426A (ko) 2006-11-23
ATE446759T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
US6221915B1 (en) Pharmaceutical compositions
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
MX2009011900A (es) Curacion de herida diabetica.
WO2004100893A3 (fr) Methodes de traitement d'affections inflammatoires a l'aide de ct-3 ou de ses analogues
WO2001047913A3 (fr) Derives substitues d'acide n-benzyl-indol-3-yl-glyoxalique a action antitumorale
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EA201100916A1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
MA28036A1 (fr) Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
NO20053032L (no) Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon.
TW200626133A (en) Oral medication for twice-daily administration
WO2005060939A3 (fr) Formulation pharmaceutique a liberation controlee
US20080293804A1 (en) Pharmaceutical Nasal Spray Formulation of Acetaminophen (paracetamol)
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
JP2001089371A (ja) ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤